MediPines Sponsors 8th Annual CPGLO Summit, Hosted by UC San Diego

LA JOLLA, CA / ACCESSWIRE / August 13, 2024 / Medipines (https://www.medipines.com) the pioneer in non-invasive cardiorespiratory assessment technology and maker of the AGM100, is proud to sponsor the 8th Annual Center for Physiological Genomics of Low Oxygen (CPGLO) Summit at UC San Diego. The summit will feature esteemed speakers Gordon Mitchell, Ph.D., and Jack Feldman, Ph.D., who will share insights into their groundbreaking research.

The CPGLO is a multi-department collaboration led by Dr. Tatum Simonson and aims to bridge the disciplines of physiology and genetics of low oxygen. The summit focuses on physiological and genomic responses to low oxygen environments, and will take place on August 28, 2024, at the Martin Johnson House, UC San Diego.

"We are honored to be hosting the esteemed scientists Dr. Mitchell and Dr. Feldman to speak at the CPGLO Summit" said Tatum Simonson Associate Professor, Co-Director of the CPGLO Summit and John B. West Endowed Chair in Respiratory Physiology from the Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology.

"The genomic response to low oxygen is an important research area that will open up avenues for new discoveries. Oxygen Deficit, pioneered by Dr. West, is central to the MediPines AGM100, which allows the clinical community to precisely detect problems with pulmonary gas exchange. We are honored to sponsor this highly relevant event in medical research," said MediPines CEO, Steve Lee.

Dr. Gordon Mitchell, a Professor of Neuroscience at the University of Florida, is renowned for his work on neuroplasticity in the neural systems controlling breathing. He is the founder and director of the UF Center for Breathing Research and Therapeutics (BREATHE) and deputy director of the UF McKnight Brain Institute. Dr. Jack Feldman, a Distinguished Professor of Neurobiology from UCLA specializes in the neurological aspects of ventilatory control and has made significant contributions to understanding how the brain regulates breathing.

The CPGLO Summit is a vital platform for researchers to discuss advancements in low oxygen research, with implications for understanding high-altitude adaptation and cellular responses to hypoxia. The work presented at these summits has wide-ranging applications, from exploring genetic adaptations in high-altitude populations to understanding cellular mechanisms that respond to low oxygen conditions. This aligns with the legacy and favorite field of John B. West, highlighting significant progress in how we adapt to live in high-altitude environments.

After introductory notes, Dr. Mitchell and Dr. Feldman will deliver their presentations, followed by a brief Q&A session. Medipines will also have a booth at the summit, providing attendees the opportunity to learn more about their innovative pulmonary gas exchange technology. This event promises to be an inspiring convergence of ideas and insights from top experts in the field.

More information on the event can be accessed here: https://pulmonary.ucsd.edu/research/labs-centers/cpglo/index.html

About MediPines

Orange County, California-based MediPines (https://www.medipines.com) is a pioneer and market-leader in non-invasive cardiorespiratory assessment technology. The company's mission is to advance respiratory medicine by providing physiology-based cardiorespiratory devices that enhance clinical effectiveness and achieve superior patient outcomes. The company's MediPines AGM100 is an industry award-winning, FDA-cleared, advanced pulmonary gas exchange technology that provides critical cardiorespiratory measures instantly and is used by medical providers and clinicians to raise diagnostic accuracy, improve treatment decisions, and accelerate healthcare decision-making.

Contact:

Sammy Lee
email: dslee@medipines.com
phone: +19493780636



View the original press release on accesswire.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.